Recent unbiased, genome-wide investigations to identify potential targets for combination therapies centered on Src inhibitors identified ILK, in association with α-Parvin and PINCH-1 as a central determinant of sensitivity to the Src/Abl kinase inhibitor, bosutinib in breast cancer [68]. This evidence concerns the gene ILK and breast carcinoma.